Seroepidemiology of mumps in the general population of Jiangsu province, China after introduction of a one-dose measles-mumps-rubella vaccine.
Seroepidemiology of mumps in the general population of Jiangsu province, China after introduction of a one-dose measles-mumps-rubella vaccine.
复制标题
引进一剂麻疹-腮腺炎-风疹疫苗后中国江苏省普通人群流行性腮腺炎的血清流行病学
DOI：
10.1038/srep14660
复制
发表时间：
2015-10-01
影响因子：
4.6
通讯作者：
Min J
中科院分区：
文献类型：
--
作者：
Liu Y;Hu Y;Deng X;Wang Z;Lu P;Ma F;Zhou M;Liu P;Min J
2004年至2011年流行性腮腺炎监测数据显示，2008年中国接种麻疹-流行性腮腺炎-风疹疫苗后，流行性腮腺炎发病率居高不下。为全面了解江苏省普通人群流行性腮腺炎免疫状况，2012年开展了江苏省普通人群流行性腮腺炎免疫球蛋白横断面调查。江苏省2004-2013年平均发病率为15.2/10万。在引入单剂MMR疫苗后，每年都会观察到两个腮腺炎发病率高峰。血清阳性率在不同地区和性别之间没有显著差异，而GMC在地区和性别上有显著差异。江苏省GMC99.1 IU/ml(95%CI：90.1~108.2)，而血清阳性率仅为5 9.1%(95%CI：5 6.5~61.6)。接种一剂MMR疫苗的两个年龄组的血清感染率分别为42.6%和70.0%，报告接种率超过95%。有关6岁以下儿童的发病率、MMR覆盖率和血清阳性率的数据表明，应该考虑采用两剂MMR策略。应加强对6-11岁和12-17岁儿童的流行性腮腺炎监测，因为他们的接触率较高，血清感染率相对较低。
The mumps surveillance data from 2004 to 2011 showed that the incidence of mumps remained high after the one-dose measles-mumps-rubella (MMR) vaccine was introduced in China in 2008. A cross-sectional survey of mumps IgG in the general population of Jiangsu province was conducted in 2012 to gain comprehensive information on the immunity profile of the general population. The mean incidence was 15.2 per 100 000 individuals in Jiangsu province from 2004–2013. Two mumps incidence peaks were observed each year after introduction of the one-dose MMR vaccine. The seroprevalence did not significantly differ by region or sex, while the GMC significantly differed by region and sex. The overall GMC in Jiangsu province was 99.1 IU/ml (95% CI: 90.1–108.2), while the seroprevalence was only 59.1% (95% CI: 56.5–61.6). The seroprevalences for the 2 age groups that received the one-dose MMR vaccine, with reported coverage exceeding 95%, were 42.6% and 70.0%, respectively. The data on the incidence, MMR coverage, and seroprevalence in children younger than 6 years of age indicate that a two-dose MMR strategy should be considered. Mumps surveillance should be strengthened in children aged 6–11 and in those aged 12–17 because of their high contact rates and relatively low seroprevalences.